Secondary KIT mutations: the GIST of drug resistance and sensitivity

Pharmacological targeting of KIT in gastrointestinal stromal tumours has dramatically changed the clinical outcome of this disease. Tyrosine kinase inhibitors are the cornerstone of this improvement, but resistance occurs through secondary KIT mutations. Studies aimed at improving our understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Andrea, Vincenzi, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461933/
https://www.ncbi.nlm.nih.gov/pubmed/30792534
http://dx.doi.org/10.1038/s41416-019-0388-7
Descripción
Sumario:Pharmacological targeting of KIT in gastrointestinal stromal tumours has dramatically changed the clinical outcome of this disease. Tyrosine kinase inhibitors are the cornerstone of this improvement, but resistance occurs through secondary KIT mutations. Studies aimed at improving our understanding of the molecular basis of sensitivity and resistance will soon allow us to further tailor our therapeutic strategies.

Ejemplares similares